drugset / Trial / NCT01717625

The Efficacy and Safety of Montelukast Sodium in the Prevention of Bronchopulmonary Dysplasia

NCT01717625

RandomizedParallel-groupOpen-labelPrevention

Summary

This study is multicentered, prospective, randomized, opened, parallel, intervention study. The aim of this study is to evaluate the efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia (BPD) in preterm infant, below 32weeks gestational age. The investigators evaluate the first effectiveness through the morbidity and mortality of bronchopulmonary dysplasia. And then, the investigators evaluate the second effectiveness through the oxygen index, the usage of mechanical ventilator about taking medicine after 2 Weeks, Oxygen Utilization After 4 Weeks, Proinflammatory Cytokine through the bronchial lavage fluid.

Timeline

Start
2011-11
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Montelukast Other / unclassified 0.5 mg
Subject Montelukast Other / unclassified 1 mg
Subject Montelukast Other / unclassified 1.5 mg
Subject Montelukast Other / unclassified 2 mg